Should biologics for psoriasis be interrupted in the era of COVID-19?

08:00 EDT 18th March 2020 | BioPortfolio

Summary of "Should biologics for psoriasis be interrupted in the era of COVID-19?"

No Summary Available


Journal Details

This article was published in the following journal.

Name: Journal of the American Academy of Dermatology
ISSN: 1097-6787


DeepDyve research library

PubMed Articles [1134 Associated PubMed Articles listed on BioPortfolio]

Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial.

Biologics revolutionized the treatment of psoriasis. Biologics are given in a fixed dose, but lower doses might be possible.

Translating the 2019 AAD-NPF Guidelines of Care for the Management of Psoriasis With Biologics to clinical practice.

In February 2019, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released a novel set of guidelines regarding the use of biologics to manage adult patients with ...

Systemic therapies in psoriasis: an update on newly approved and pipeline biologics and oral treatments.

Although there are numerous biologics and several oral treatments for psoriasis, a number of promising systemic therapies are on the horizon. Knowledge of these medications might help guide our treatm...

Predicting the Long-term Outcomes of Biologics in Psoriasis Patients using Machine Learning.

Despite the vast amount of data on the efficacy of biologics in psoriasis treatment, therapeutic decision-making is still based on a trial-and-error approach. In a real world setting over 50% of patie...

Risankizumab versus adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal.

Patients with moderate-to-severe plaque psoriasis have greatly benefited from the availability of biologics. However, treatment-selection can be challenging and it is important that with growing numbe...

Clinical Trials [1244 Associated Clinical Trials listed on BioPortfolio]

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity

Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with sta...

Therapeutic Drug Monitoring of Seckinumab in Psoriasis Patients.

Biologics such as secukinumab are currently the most effective treatment option for patients with moderate to severe psoriasis. But they are costly for healthcare systems and still describ...

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

Biologics, such as brodalumab, are currently the most effective treatment option for patients with moderate-to-severe psoriasis. But they are costly for health care systems and prescribed ...

Medical and Biotech [MESH] Definitions

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

Dioxygenases that catalyze the peroxidation of methylene-interrupted UNSATURATED FATTY ACIDS.

A contraceptive method whereby coitus is purposely interrupted in order to prevent EJACULATION of SEMEN into the VAGINA.

A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.

A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.

Quick Search

DeepDyve research library

Relevant Topics

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Searches Linking to this Article